Onco-Innovations Limited (NEO:ONCO)

Market Cap	103.32M
Revenue (ttm)	n/a
Net Income (ttm)	-64.37K
Shares Out	52.71M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,762
Average Volume	184,390
Open	1.970
Previous Close	2.020
Day's Range	1.800 - 1.990
52-Week Range	0.560 - 2.800
Beta	n/a
RSI	53.51
Earnings Date	Aug 1, 2025

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3′-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Thomas O’Shaughnessy
• Employees: 1
• Stock Exchange: Cboe Canada
• Ticker Symbol: ONCO